1504 Federal Register / Vol. 86, No. 5 / Friday, January 8, 2021 / Notices 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

March 9, 2021. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number ll, Room C4–26–05, 

7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

2. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10198—Creditable Coverage 

Disclosure to CMS On-Line Form and 

Instructions 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Creditable 

Coverage Disclosure to CMS On-Line 

Form and Instructions; Use: Most 

entities that currently provide 

prescription drug benefits to any 

Medicare Part D eligible individual 

must disclose whether their prescription 

drug benefit is creditable (expected to 

pay at least as much, on average, as the 

standard prescription drug plan under 

Medicare). The disclosure must be 

provided annually and upon any change 

that affects whether the coverage is 

creditable prescription drug coverage. 

Form Number: CMS–10198; Frequency: 

Annually; Affected Public: Individuals 

and Households, State, Local, or Tribal 

Governments, Federal Government; 

Number of Respondents: 110,217; 

Number of Responses: 110,217; Total 

Annual Hours: 9,185. (For questions 

regarding this collection, contact 

Tammie Hill at (410) 786–3317.) 

Dated: January 4, 2021. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2021–00074 Filed 1–7–21; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–3728] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Collection of 

Information for Participation in the 

Food and Drug Administration NonEmployee Fellowship and Traineeship 

Programs 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on ‘‘Collection of 

Information for Participation in FDA 

Non-Employee Fellowship and 

Traineeship Programs.’’ 

DATES: Submit either electronic or 

written comments on the collection of 

information by March 9, 2021. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before March 9, 

2021. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of March 9, 2021. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 86, No. 5 / Friday, January 8, 2021 / Notices 1505 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2018–N–3728 for ‘‘Collection of 

Information for Participation in FDA 

Non-Employee Fellowship and 

Traineeship Programs.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

FOR FURTHER INFORMATION CONTACT: 

Amber Sanford, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–8867, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3521), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes Agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

Agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Collection of Information for 

Participation in FDA Non-Employee 

Fellowship and Traineeship Programs 

OMB Control Number 0910—NEW 

In compliance with 44 U.S.C. 3507, 

FDA will submit to OMB a request to 

review and approve a new collection of 

information: ‘‘Collection of Information 

for Participation in FDA Non-Employee 

Fellowship and Traineeship Programs.’’ 

Section 746(b) of the Federal Food, Drug 

and Cosmetic Act (21 U.S.C. 379l(b)) 

allows FDA to conduct and support 

intramural training programs through 

fellowship and traineeship programs. 

These mandatory collection forms 

provide FDA with information from the 

non-employee to: (1) Begin the program, 

(2) administer the program, (3) 

coordinate training, and (4) end the 

program. 

1. To begin the program, the nonemployee must submit the following 

information: (A) New non-employee 

data form; (B) proof of health insurance; 

(C) emergency contact information; (D) 

unified financial management system 

(UFMS) supplier and site information 

for stipend payments, financial 

information; and (E) CONCUR GOV 

New Traveler Profile Form. 

(A) New non-employee data form to 

begin onboarding process—The New 

Non-Employee Data form collects 

information that includes: (1) Name; (2) 

gender; (3) birthplace; (4) date of birth; 

(5) email; (6) home address; (7) FDA 

center/organization/supervisor; (8) 

citizenship; (9) Social Security number 

(SSN); (10) start date; (11) end date; (12) 

contract information; (13) location; and 

(14) question regarding current or 

previous Federal work experience. 

(B) Proof of health insurance— 

Participants in FDA fellowship and 

traineeship programs will be asked for 

certain information to demonstrate 

proof of health insurance: (1) Name of 

health insurance plan provider; (2) 

name/contact information of primary 

member; (3) member identification 

number/group number; (4) begin date/ 

policy expiration date; and (5) signature. 

The purpose of the health insurance 

information is for FDA to substantiate 

that participants of the program are 

covered by health insurance. 

(C) Emergency contact information— 

Participants in FDA fellowship and 

traineeship programs will be asked for 

certain information about emergency 

contact demographics: (1) Name of 

fellow/trainee; (2) center; (3) name of 

emergency contact; (4) telephone 

number of emergency contact; and (5) 

relationship to contact. The purpose of 

emergency contact information of 

fellows/trainees is to ensure there is a 

primary contact should emergencies 

arise. 

(D) UFMS supplier and site 

information for stipend payments, 

financial information—Participants in 

FDA fellowship and traineeship 

programs will be asked for their 

financial institution routing number and 


tkelley on DSKBCP9HB2PROD with NOTICES
1506 Federal Register / Vol. 86, No. 5 / Friday, January 8, 2021 / Notices 

account information for direct deposit of 

stipend payments: (1) Name; (2) 

taxpayer ID or SSN; (3) classification/ 

vendor type; (4) payment options 

(electronic payment only); (5) mailing 

address; (6) bank/financial institution 

information (name, routing number, 

account number, account type); and (7) 

signature. The purpose of the financial 

information is for FDA to process a 

direct deposit transaction for a monthly 

stipend payment. 

(E) CONCUR GOV new traveler 

profile form—Participants in FDA’s 

non-employee scientist programs may 

be asked to travel and will need to 

complete an online profile for the 

Concur Government Edition (CGE) 

System, which requires the following 

information: (1) Personal information 

(name, Agency, office/operating 

division, residence city, residence state, 

signatures); (2) Agency information (ID 

#, title, center accounting number); (3) 

business contact information; (4) email 

addresses; emergency contact; (5) travel 

preferences (preferred airline, hotel, 

airline seats, frequent flyer number); (6) 

credit card number; (7) banking account 

for reimbursement; and (8) approving 

signatures. The CGE profile provides 

assistance to travel preparers who are 

booking travel for FDA program 

participants. 

2. To administer the program, nonemployee scientists must submit 

information for: (A) Absence recording 

form; (B) personal custody property 

record; (C) FDA health summary; and 

(D) discovery and invention. 

(A) Absence recording form— 

Participants in FDA fellowship and 

traineeship programs will be asked for 

certain information about tracking 

attendance and absences: (1) Name of 

fellow/trainee; (2) office/division of 

placement; (3) mentor/sponsor name; (4) 

type of absence; (5) dates of absence; (6) 

reason for absence; and (7) mentor/ 

sponsor approval. The purpose of 

tracking attendance and absences for 

fellows/trainees is to determine the 

monthly stipend payment and potential 

modifications to purchase orders for 

extended absences. 

(B) Personal custody property 

record—Participants in FDA fellowship 

and traineeship programs will be 

required to sign the property request, 

acknowledging personal responsibility 

for government property. The plan 

collects the following information: (1) 

Fellow/trainee name; (2) operative 

division/division; (3) location; (4) 

telephone; (5) description of items; (6) 

items to be returned; (7) return date; (8) 

fellow/trainee signature; (9) custodial 

officer signature; and (10) issuing office. 

The purpose of this record is to 

acknowledge that an individual has 

received government property and 

accepts personal responsibility for items 

issued to perform their roles. 

(C) FDA health summary— 

Participants in FDA fellowship and 

traineeship programs will be asked for 

information about health for laboratory 

activities. The FDA Occupational Health 

Services Health Summary form collects 

information that includes: (1) Name; (2) 

program; (3) email; (4) work phone; (5) 

FDA mentor; (6) center/office division; 

(7) location; (8) date; (9) primary care 

physician and contact information; (10) 

immunizations; (11) social history; (12) 

relationship history; (13) allergies; and 

(14) medical history. 

(D) Discovery and invention— 

Participants in FDA fellowship and 

traineeship programs will be asked for 

information about discoveries and 

inventions at FDA. The discovery and 

invention report collects information 

that includes: (1) Title of discovery; (2) 

description of discovery; (3) 

identification of collaborators, 

cooperative research and development 

agreement, and human materials or 

subjects; (4) publications; (5) technology 

stage; (6) commercial potential; and (7) 

competition, potential users, and 

manufacturers. 

3. For the coordination of training, 

non-employee scientists must complete 

information for the: (A) Training 

development plan; (B) final project 

report; (C) training request; (D) travel 

request; (E) Learning Management 

System (LMS) request; (F) standard 

operating procedures (SOP) verification; 

and (G) program evaluation. 

(A) Training development plan— 

Participants in FDA fellowship and 

traineeship programs will be required to 

develop the individual plan in 

partnership with their mentor. The plan 

collects the following information: (1) 

Fellow/trainee name; (2) mentor(s)/ 

preceptor(s) name; (3) sign-on date; (4) 

year 1 goals, courses/training, regulatory 

activities, and completion date; (5) year 

2 goals, courses/trainings, regulatory 

activities, and completion date; (6) 

fellow/trainee signature; and (7) 

mentor(s)/preceptor(s) signature. The 

purpose of this individual development/ 

training plan is to have a record of 

mandatory training and specific goals 

and tasks for the contributions and/or 

completion of a project. 

(B) Final project report—Participants 

in FDA fellowship and traineeship 

programs will be required to complete 

the final report in partnership with their 

mentor. The plan collects the following 

information: (1) Fellow/trainee name; 

(2) mentor/preceptor name; (3) goals; (4) 

objectives; (5) alignment with center or 

FDA goals; (6) project summary/ 

abstract; (7) accomplishments; and (8) 

impact on public health. The purpose of 

this report is to acknowledge the 

contributions to the overall project and 

identify performance successes or 

challenges. The collection of 

information is mandatory to participate 

in FDA’s fellowship and traineeship 

programs. 

(C) Training request—Participants in 

FDA fellowship and traineeship 

programs will be asked to identify the 

following for external training requests: 

(1) Name of fellow/trainee; (2) operating 

office/staff division; (3) title and topic of 

training; (4) name of hosting Agency/ 

organization; (5) purpose/justification 

for external training; (6) dates; (7) 

location; and (8) approving signatures. 

The purpose of the external training 

request is to provide justification 

substantiating the benefits to the 

operating office/staff division and/or 

benefits to the fellow’s/trainee’s 

professional development and training. 

The collection of information is 

mandatory to participate in FDA’s 

fellowship and traineeship programs. 

(D) Travel request—Participants in 

FDA fellowship and traineeship 

programs will be asked for certain 

information about travel requests and 

authorizations/approvals: (1) Office/ 

division; (2) research project title; (3) 

mentor/sponsor name; (4) mentor/ 

sponsor email and telephone; (5) fellow/ 

trainee name; (6) appointment period; 

(7) funding source and fiscal year; (8) 

brief description of travel; (9) 

anticipated travel dates; and (10) travel 

justification and relation to project. The 

purpose of authorization for travel of 

fellows/trainees is to determine if the 

travel has been approved by the 

sponsor/mentor and if the travel is a 

mission-related activity to the fellow/ 

trainee training plan or appointment/ 

assignment. The collection of 

information is mandatory to participate 

in FDA’s fellowship and traineeship 

programs. 

(E) LMS access—Participants in FDA 

fellowship and traineeship programs 

will be asked for information to obtain 

access to the LMS: (1) Name; (2) 

location; (3) organizational unit; and (4) 

email address. The purpose of LMS 

access request is to obtain information 

of non-employee scientists to ensure 

they have access to receive training and 

educational opportunities offered in the 

Health and Human Services LMS 

System. 

(F) SOP verification—Participants in 

FDA fellowship and traineeship 

programs will be asked for certain 

information to verify that they have read 

and received instructional training on 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 86, No. 5 / Friday, January 8, 2021 / Notices 1507 

the SOPs for said program. The form 

collects the following: (1) Name; (2) 

signature; (3) date; and (4) center. 

(G) Program evaluation—Participants 

in FDA fellowship and traineeship 

programs will be asked to complete an 

evaluation providing program data that 

will be synthesized into program reports 

on the overall effectiveness of the 

program. The evaluation collects the 

following information: (1) Demographic 

data; (2) expectations of fellowship or 

training program; (3) administration 

processes and support to fellow or 

trainee; (4) FDA retention and plans of 

fellow or trainee; (5) training and 

education completed; and (6) 

professional/research goals. The 

purpose of this evaluation is to assess 

the effectiveness of the program and 

feedback from participants to improve 

the quality of the experience. 

4. To end the program, a nonemployee must submit the exit 

checklist—Participants in FDA 

fellowship and traineeship programs 

may be asked to complete the exit 

checklist to manage the exit process and 

return of FDA property. The exit 

checklist guides the exit process for the 

following operational components: (1) 

Access key/pass; (2) accountable 

property; (3) system applications 

inactive; (4) library materials; (5) 

government-issued documents (i.e., 

passports); (6) personal identity 

verification card/badge; (7) borrowed 

records; (8) employee records; and (9) 

information technology accounts. 

All exit information will be entered to 

terminate access to any FDA 

information. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Activity Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average burden per 

response Total hours 

New Non-Employee Data Form ............................... 1,220 1 1 0.25 (15 minutes) ...... 305 

Proof of Health Insurance ........................................ 600 1 1 0.25 (15 minutes) ...... 150 

Emergency Contact Information .............................. 1,220 1 1 0.25 (15 minutes) ...... 305 

UFMS Supplier and Site Information for Stipend 

Payments, Financial Information.

600 1 1 0.25 (15 minutes) ...... 150 

CONCUR GOV New Traveler Profile ...................... 620 1 1 0.25 (15 minutes) ...... 155 

Absence Recording Form ........................................ 1,220 1 1 0.25 (15 minutes) ...... 305 

Personal Custody Property Record ......................... 1,220 1 1 0.25 (15 minutes) ...... 305 

FDA Health Summary .............................................. 1,220 1 1 1 ................................ 1,220 

Discovery and Invention Form ................................. 1,220 1 1 1 ................................ 1,220 

Training Development Plan ..................................... 1,220 1 1 1 ................................ 1,220 

Final Project Report ................................................. 1,220 1 1 1 ................................ 1,220 

Training Request ...................................................... 610 1 1 0.5 (30 minutes) ........ 305 

Travel Request ......................................................... 610 1 1 0.5 (30 minutes) ........ 305 

LMS Access ............................................................. 1,220 1 1 0.25 (15 minutes) ...... 305 

SOP Verification ....................................................... 1,220 1 1 0.25 (15 minutes) ...... 305 

Program Evaluation ................................................. 1,220 1 1 0.5 (30 minutes) ........ 610 

Exit Checklist ........................................................... 1,220 1 1 1 ................................ 1,220 

Total .................................................................. 9,605 

1 There are no capital costs or operating and maintenance costs associated with this collection of information. 

FDA published a 60-day notice for 

this information collection on 

November 22, 2019 (84 FR 64536). FDA 

is reopening the 60-day comment period 

in order to satisfy PRA requirements. No 

changes have been made to the 

information collection. 

Dated: January 4, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–00120 Filed 1–7–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–0417] 

Request for Nominations on the 

National Mammography Quality 

Assurance Advisory Committee 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting that 

any industry organizations interested in 

participating in the selection of 

nonvoting industry representatives to 

serve on the National Mammography 

Quality Assurance Advisory Committee 

in the Center for Devices and 

Radiological Health notify FDA in 

writing. FDA is also requesting 

nominations for nonvoting industry 

representatives to serve on the National 

Mammography Quality Assurance 

Advisory Committee. A nominee may 

either be self-nominated or nominated 

by an organization to serve as a 

nonvoting industry representative. 

Nominations will be accepted for 

current vacancies effective with this 

notice. 

DATES: Any industry organization 

interested in participating in the 

selection of appropriate nonvoting 

members to represent industry interests 

must send a letter stating that interest to 

FDA by February 8, 2021 (see sections 

I and II of this document for further 

details). Concurrently, nomination 

materials for prospective candidates 

should be sent to FDA by February 8, 

2021. 

ADDRESSES: All statements of interest 

from industry organizations interested 

in participating in the selection process 

of nonvoting industry representative 

nominations should be sent to Margaret 

Ames (see FOR FURTHER INFORMATION


tkelley on DSKBCP9HB2PROD with NOTICES